STL Index for: Dabrafenib

The Role of Skin Care in Oncology Patients

The consensus paper aims to identify the impact on patients of skin toxicities associated with cancer treatment and evidence-based best practices for skincare to minimize or prevent these changes.

Update on Immunotherapeutics in the Management of Metastatic Melanoma

There are many new immunotherapeutics that have been approved or are in clinical and pre-clinical trials to expand our arsenal in the treatment of melanoma and other previously difficult to treat malignancies.

Skin Treatments Introduced in 2014

An overview and update of skin treatments introduced in 2014: Quick overview of drug name, indications and regulatory status. Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Doxycycline hyclate tablets (Acticlate™), Tretinoin gel microsphere 0.08% (Retin-A Micro®) and many other drugs are covered.

Update on Drugs and Drug News: March-April 2014

Update on Trametinib + Dabrafenib (Mekinist® + Tafinlar®), Tretinoin gel microsphere 0.08% (Retin-A Micro®), Fluocinonide cream 0.1%, Hydrogel wound dressing (Loutrex®), Scar treatment (Microcyn®)

Skin Treatments Introduced in 2013

An overview and update of skin treatments introduced in 2013: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% + benzoyl peroxide 2.5% gel (Epiduo®), Ingenol mebutate gel (0.015%, 0.05%) (Picato®), Efinaconazole 10% topical solution (Jublia®) and many other drugs are covered.

Update on Drugs and Drug News: September-October 2013

Update on Dabrafenib mesilate capsule (Tafinlar™), Trametinib dimethyl sulfoxide tablet (Mekinist™), and Vismodegib capsule (Erivedge®)

Update on Drugs and Drug News: July-August 2013

Update on Dabrafenib mesilate capsule (Tafinlar®), Trametinib dimethyl sulfoxide tablet (Mekinist™), and Vismodegib capsule (Erivedge®)

POPULAR